Antiviral ensitrelvir cuts risk of COVID-19 in household contacts by two-thirds, study finds

medicalxpress - The antiviral drug ensitrelvir prevents infection in household contacts of COVID-19 patients when given within 72 hours after symptom onset in the index patient, according to a Phase III randomized controlled trial published in the New England Journal of …

AI Summary: A randomized trial shows the oral antiviral ensitrelvir, used as post‑exposure prophylaxis, reduced the risk of symptomatic COVID‑19 in household contacts by roughly two‑thirds. The finding suggests a practical option for preventing spread after close exposure, offering public‑health teams a less dramatic but highly useful tool than lockdowns.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

One hepatitis B drug shows early functional cures in trial / 2 days

FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 13 days

Gene therapy pioneers win Breakthrough Prize for CRISPR sickle‑cell work / 6 wks

First‑in‑human CRISPR/Cas12a sickle cell therapy treated; gene editing shows promise / 1 month

Denali drug receives accelerated approval for rare CNS indication / 2 months

Moderna reaches multibillion-dollar settlement over mRNA patents / 2 months

First-in-human trial primes immune system to accept donor livers / 6 wks